Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.

Trial Profile

Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 15 Jul 2009 Actual initiation date (1 Jan 2007) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Actual end date (1 Sep 2007) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT00938899).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top